Erratum: Pharmacogenomics in clinical practice and drug development (Nature Biotechnology (2012) 30 (1117-1124) DOI: 10.1038/nbt.2424);Pharmacogenomics in clinical practice and drug development

Nature Biotechnology

Volumn 30, Issue 11, 2012, Pages 1117-1124

  Harper, Andrew R ^a,b   Topol, Eric J ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; GENES;

CARBAMAZEPINE; CLINICAL PRACTICES; DRUG CANDIDATES; DRUG DEVELOPMENT; GENOME-WIDE ASSOCIATION STUDIES; PHARMACOGENOMICS; SEQUENCE VARIANTS; WHOLE GENOME SEQUENCING;

PATIENT TREATMENT;

ADALIMUMAB; ALPHA INTERFERON; ALPHA2B INTERFERON; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIDEPRESSANT AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CARBAMAZEPINE; CITALOPRAM; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; ETANERCEPT; FLUCLOXACILLIN; GLUCOCORTICOID; ILOPERIDONE; INFLIXIMAB; LUMIRACOXIB; METFORMIN; METHOTREXATE; METHYLPHENIDATE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; ROFECOXIB; ROSIGLITAZONE; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TUMOR NECROSIS FACTOR INHIBITOR; WARFARIN; XIMELAGATRAN;

ATTENTION DEFICIT DISORDER; CLINICAL PRACTICE; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; EXOME; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER TOXICITY; OSTEOARTHRITIS; PATIENT CODING; PHARMACOGENOMICS; PHENOTYPE; PRESCRIPTION; PRIORITY JOURNAL; RASH; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; STEVENS JOHNSON SYNDROME;

EID: 84869396522     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1212-1249e     Document Type: Erratum

References (83)

1. Allison, M. Reinventing clinical trials. Nat. Biotechnol. 30, 41-49 (2012
2. Mullard, A. Partnering between pharma peers on the rise. Nat. Rev. Drug Discov. 10, 561-562 (2011
3. Norman, T.C., Bountra, C., Edwards, A.M., Yamamoto, K.R. & Friend, S.H. Leveraging crowdsourcing to facilitate the discovery of new medicines. Sci. Transl. Med. 3, 88mr1 (2011
4. Pollack, A. Drug makers join efforts in research. The New York Times, B3 (2012
5. Hindorff, L.A. et al. A catalog of published genome-wide association studies. (accessed 22 October 2012)
6. Giacomini, K.M. et al. Pharmacogenomics and patient care: One size does not fit all. Sci Transl Med 4, 153ps118 (2012
7. Pirmohamed, M. Pharmacogenetics: past, present and future. Drug Discov. Today 16, 852-861 (2011
8. Nelson, M.R. et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science 337, 100-104 (2012
9. Ramirez, A.H. et al. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J. advance online publication, doi:10.1038/tpj.2012.14 (15 May 2012
10. Rosen, H.R. Chronic hepatitis C infection. N. Engl. J. Med. 364, 2429-2438 (2011
11. Soriano, V. et al. Pharmacogenetics of hepatitis C. J. Antimicrob. Chemother. 67, 523-529 (2012
12. McHutchison, J.G. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361, 580-593 (2009
13. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009
14. Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon- alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109 (2009
15. Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat. Genet. 41, 1100-1104 (2009
16. Rauch, A. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology 138, 1338-1345, 1345 e1331-1337 (2010
17. Veldt, B.J. et al. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am. J. Transplant. 12, 737-744 (2012
18. Clark, P.J., Thompson, A.J. & McHutchison, J.G. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: The future of personalized HCV therapies. Am. J. Gastroenterol. 106, 38-45 (2011
19. Thomas, D.L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801 (2009
20. Topol, E.J. & Teirstein, P.S. Textbook of Interventional Cardiology 6th edn. (Elsevier Saunders, 2011
21. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J. Am. Med. Assoc. 302, 849-857 (2009
22. Mega J.L. et al. Dosing clopidogrel based on cyp2c19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. J. Am. Med. Assoc. 306, 2221-2228 (2011
23. Roberts, J.D. et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): A prospective, randomised, proof-of-concept trial. Lancet 379, 1705-1711 (2012
24. Patay, B.A. & Topol, E.J. The unmet need of education in genomic medicine. Am. J. Med. 125, 5-6 (2012
25. Moore, T.J., Furberg, C.D. & Cohen, M.R. Anticoagulants the leading reported drug risk in 2011. QuarterWatch, Monitoring FDA MedWatch Reports (Institute for Safe Medication Practices, 2012). (accessed 22 October 2012)
26. Klein, T.E. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009
27. Epstein, R.S. et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55, 2804-2812 (2010
28. Anderson, J.L. et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125, 1997-2005 (2012
29. Shu, Y. et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83, 273-280 (2008
30. Zhou, K. et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 43, 117-120 (2011
31. Tantisira, K.G. et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am. J. Respir. Crit. Care Med. 185, 1286-1291 (2012
32. Tantisira, K.G. et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 365, 1173-1183 (2011
33. Himes, B.E. et al. Genome-Wide Association Analysis in Asthma Subjects Identifies SPATS2L as a Novel Bronchodilator Response Gene. PLoS Genet. 8, e1002824 (2012
34. Jonsson, T. et al. A mutation in APP protects against Alzheimer/'s disease and agerelated cognitive decline. Nature 488, 96-99 (2012
35. Smith, D.A. & Schmid, E.F. Drug withdrawals and the lessons within. Curr. Opin. Drug Discov. Devel. 9, 38-46 (2006
36. Lynch, T. & Price, A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician 76, 391-396 (2007
37. Daly, A.K. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu. Rev. Pharmacol. Toxicol. 52, 21-35 (2012
38. Lee, W.M. Drug-induced hepatotoxicity. N. Engl. J. Med. 349, 474-485 (2003
39. Kindmark, A. et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8, 186-195 (2008
40. Daly, A.K. et al. HLA-B.*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816-819 (2009
41. Lucena, M.I. et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141, 338-347 (2011
42. Roujeau, J.C. Clinical heterogeneity of drug hypersensitivity. Toxicology 209, 123-129 (2005
43. McCormack, M. et al. HLA-A.*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134-1143 (2011
44. Chen, P. et al. Carbamazepine-induced toxic effects and HLA-B.*1502 screening in Taiwan. N. Engl. J. Med. 364, 1126-1133 (2011
45. Link, E. et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med. 359, 789-799 (2008
46. Wilke, R.A. et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92, 112-117 (2012
47. Furberg, C.D. & Pitt, B. Withdrawal of cerivastatin from the world market. Curr. Control. Trials Cardiovasc. Med. 2, 205-207 (2001
48. Zhang, W., Roederer, M.W., Chen, W.Q., Fan, L. & Zhou, H.H. Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics 13, 223-231 (2012
49. Doshi, P., Jefferson, T. & Del Mar, C. The imperative to share clinical study reports: Tecommendations from the Tamiflu experience. PLoS Med. 9, e1001201 (2012
50. Schnitzer, T.J. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Tandomised controlled trial. Lancet 364, 665-674 (2004
51. Singer, J.B. et al. A genome-wide study identifies HLA alleles associated with lumiracoxib- related liver injury. Nat. Genet. 42, 711-714 (2010
52. Aithal, G.P. & Daly, A.K. Preempting and preventing drug-induced liver injury. Nat. Genet. 42, 650-651 (2010
53. Shih, J.Y., Gow, C.H. & Yang, P.C. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N. Engl. J. Med. 353, 207-208 (2005
54. Geyer, C.E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006
55. Berry, D.A. Adaptive clinical trials in oncology. Nat. Rev. Clin. Oncol. 9, 199-207 (2012
56. Barker, A.D. et al. I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97-100 (2009
57. Ramsey, B.W. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663-1672 (2011
58. Sarepta Therapeutics announces eteplirsen meets primary endpoint of increased novel dystrophin. Accessed 16 October 2012.
59. Belluck, P. New drug trial seeks to stop Alzheimer's before it starts. The New York Times, May 16, 2012.
60. Pharmacogenomics Working Party (PGWP). (European Medicines Agency, 2011). (accessed 22 October 2012)
61. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research. E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions (International Conference on Harmonisation, 2011). (accessed 22 October 2012)
62. US Department of Health and Human Services, US Food and Drug Administration. Voluntary exploratory data submissions (VXDS). (accessed 22 October 2012)
63. Stanek, E.J. et al. Adoption of pharmacogenomic testing by US physicians: Tesults of a nationwide survey. Clin. Pharmacol. Ther. 91, 450-458 (2012
64. Topol, E.J. Pharmacy benefit managers, pharmacies, and pharmacogenomic testing: prescription for progress? Sci. Transl. Med. 2, 44cm22 (2010
65. Takeuchi, F. et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433 (2009
66. Cooper, G.M. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027 (2008
67. Turner, S.T. et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 52, 359-365 (2008
68. Turner, S.T. et al. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension 59, 1204-1211 (2012
69. Paré, G. et al. RELY-Genetics: Genetic determinants of dabigatran plasma levels and their relation to clinical response at the European Society of Cardiology 2012 Congress, Munich, August 25-29, 2012). (accessed October 22, 2012)
70. Kindmark, A. et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8, 186-195 (2008
71. McCormack, M. et al. HLA-A.*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134-1143 (2011
72. Ozeki, T. et al. Genome-wide association study identifies HLA-A.*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20, 1034-1041 (2011
73. Fellay, J. et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464, 405-408 (2010
74. Trevino, L.R. et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27, 5972-5978 (2009
75. Byun, E. et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch. Neurol. 65, 337-344 (2008
76. Liu, C. et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 14, 575-581 (2008
77. Mick, E., Neale, B., Middleton, F.A., McGough, J.J. & Faraone, S.V. Genome-wide association study of response to methylphenidate in 187 children with attentiondeficit/ hyperactivity disorder. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 147B, 1412-1418 (2008
78. Lavedan, C. et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol. Psychiatry 14, 804-819 (2009
79. Ising, M. et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry 66, 966-975 (2009
80. Garriock, H.A. et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 67, 133-138 (2010
81. van Vollenhoven, R.F. Switching between anti-tumour necrosis factors: Trying to get a handle on a complex issue. Ann. Rheum. Dis. 66, 849-851 (2007
82. Bonafede, M.M., Gandra, S.R., Watson, C., Princic, N. & Fox, K.M. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: A claims analysis. Adv. Ther. 29, 234-248 (2012
83. Krintel, S.B. et al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet. Genomics 22, 577-589 (2012